CRISPR Screening Market Report Scope & Overview:

The CRISPR Screening Market was valued at USD 2.85 Billion in 2025 and is expected to reach USD 11.89 Billion by 2035, growing at a CAGR of 15.35% from 2026-2035.

The CRISPR Screening Market covers the libraries, reagents, instruments and services researchers use to systematically knock out, silence or activate genes across the genome and observe the resulting effect on a cell. This loss-of-function and gain-of-function approach has become a standard early step in identifying which genes drive a disease process before a drug program commits resources to a specific target. Established life sciences tool makers supply the guide RNA libraries and sequencing-linked readouts that screening relies on, while specialized contract research organizations run the screens themselves for customers lacking in-house capacity. Growing commercial validation of CRISPR-based therapies is extending demand for screening further upstream, as drug developers use it to nominate and de-risk targets earlier in the discovery pipeline.

⮞Addgene, the nonprofit plasmid repository widely used by the CRISPR research community, reported in a February 5, 2026 year-in-review post that it welcomed more than 500 new depositing labs in 2025 and that materials distributed through its collection contributed to roughly 9,000 published studies that year. Growth of this kind in the base of laboratories depositing and requesting CRISPR-related reagents points to a broadening pool of researchers running genome-scale screening experiments worldwide.

U.S. CRISPR Screening Market Outlook:

The U.S. CRISPR Screening Market was valued at USD 1.00 Billion in 2025 and is expected to reach USD 4.26 Billion by 2035, growing at a CAGR of 15.60% from 2026-2035.

The U.S. carries the largest share of regional CRISPR screening spending, anchored by a dense concentration of pharmaceutical discovery units, academic genome centers and contract research organizations. Established life sciences tool makers headquartered in the country continue to expand reagent and library manufacturing capacity to meet demand without extending order lead times. Continued biopharmaceutical investment in target discovery is expected to support steady U.S. market growth through 2035.

⮞Integrated DNA Technologies said in August 2026 that its synthesis capacity in Coralville, Iowa, more than tripled earlier in 2026, and announced a new pilot lab at its Innovation Nexus in Sunnyvale, California, to speed the development and deployment of high-diversity oligonucleotide solutions. Capacity additions of this kind at a U.S.-based supplier support timely delivery of the custom guide RNA and oligonucleotide pools that CRISPR screening libraries are built from.

By Product & Services, Products Dominates the CRISPR Screening Market and Services Grows Fastest

Products hold the largest share because screening libraries, reagents and kits are the recurring consumable purchase every laboratory running a screen needs, regardless of whether it designs the screen internally or outsources the analysis to a specialized provider. Established library providers maintain catalogs spanning whole-genome and focused gene-set libraries that customers can order directly without a lengthy custom design process, and repeat orders for fresh reagent lots keep purchasing activity steady between major screening projects. This combination of recurring consumable demand and catalog breadth keeps products ahead of services in total revenue even as outsourced screening activity expands.

Services is growing fastest as pharmaceutical and biotechnology customers increasingly prefer to outsource entire screens, including library design, hit validation and sequencing-based analysis, to specialized providers rather than building internal capability from scratch. Contract research organizations offering full screening workflows let smaller biotech customers access genome-scale screening without hiring dedicated staff or purchasing instrumentation of their own. As more drug discovery programs choose this outsourced model over building internal teams, services is expected to grow faster than the broader product and services mix through 2035.

By Type, CRISPR Knockout Dominates the CRISPR Screening Market and CRISPR Activation Grows Fastest

CRISPR knockout holds the largest type share because completely disabling a gene remains the most direct and widely validated way to determine whether that gene is required for a given cellular process, making it the default first screen for most functional genomics studies. Knockout libraries and protocols are also the most mature and well-documented format, giving new laboratories entering CRISPR screening a lower barrier to adopting this approach over newer alternatives. This combination of directness and maturity keeps knockout screening as the volume leader across both academic and industry users.

CRISPR activation is growing fastest as researchers increasingly want to study what happens when a gene's expression is turned up rather than eliminated, which is especially relevant for genes whose loss has no visible effect but whose overexpression reveals a disease-relevant function. Pairing activation screens with existing knockout data lets researchers build a more complete picture of a gene's role across a disease pathway. As more drug discovery programs adopt this complementary approach, CRISPR activation is expected to grow faster than the broader type mix through 2035.

By Application, Functional Genomics Dominates the CRISPR Screening Market and Drug Discovery and Development Grows Fastest

Functional genomics holds the largest application share because academic and industry researchers use genome-wide screens as a foundational tool to map which genes contribute to a basic biological process long before any specific drug program is defined. This broad, hypothesis-generating use case spans far more laboratories and research questions than any single downstream application, keeping functional genomics as the largest application by volume of screens run. Established academic genome centers and core facilities further reinforce this base through screening services offered to researchers across many disease areas.

Drug discovery and development is growing fastest as pharmaceutical and biotechnology companies increasingly use CRISPR screening to nominate and de-risk therapeutic targets earlier in their pipelines, rather than relying solely on existing literature or prior clinical validation. Faster regulatory pathways for gene-editing therapies are reinforcing this shift by rewarding companies that can show a well-validated target before entering costly late-stage development. As more drug programs adopt this earlier screening step, drug discovery and development is expected to grow faster than the broader application mix through 2035.

⮞Revvity introduced the Opera Phenix OptIQ high-content screening system in February 2026, alongside its EnVision Nexus One plate reader and AssayMate liquid handler, raising camera quantum efficiency from 60% to 95% and adding support for 3D organoid and organ-on-chip models. Launches aimed at phenotypic screening point to continued investment in the instrumentation behind arrayed CRISPR screens with imaging-based readouts.

By End Use, Pharmaceutical and Biotechnology Companies Dominates the CRISPR Screening Market and Contract Research Organizations Grows Fastest

Pharmaceutical and biotechnology companies account for the largest end-use share because they run the largest number of screens tied directly to active drug discovery programs, each requiring target identification, validation and often multiple follow-up screens before a program advances. Internal screening groups at larger companies maintain dedicated budgets for this work across many simultaneous drug programs, unlike academic laboratories operating on smaller, project-specific grants. This concentration of well-funded, recurring screening activity keeps pharmaceutical and biotechnology companies as the largest end-use category.

Contract research organizations are the fastest-growing end-use category as more biotechnology companies, particularly smaller ones without in-house screening capability, outsource their target discovery screens entirely rather than building internal teams. As more biotechnology companies adopt this outsourced model, contract research organizations are expected to grow faster than the broader end-use mix through 2035.

Regional Analysis:

North America CRISPR Screening Market Insights

With a share of 41.80% in 2025, North America led the market. The United States anchors regional demand through its dense concentration of pharmaceutical discovery units, academic genome centers and contract research organizations, while Canada contributes through government-funded genomics research institutes. Commercial validation of CRISPR-based therapies originating from U.S. developers is reinforcing regional demand for the screening work used to identify new therapeutic targets. A deep base of established life sciences tool suppliers headquartered in the region keeps order lead times for screening libraries and reagents shorter than in most other markets.

Continued biopharmaceutical investment in target discovery, combined with a faster regulatory pathway for gene-editing therapies, is pulling CRISPR screening demand earlier into development pipelines across the region. Growing adoption of outsourced screening services is also letting smaller regional biotechnology companies access genome-scale screening without building internal capability. The region's pharmaceutical research depth and regulatory momentum keep North America ahead of other regions in overall CRISPR screening market size.

Asia Pacific CRISPR Screening Market Insights

Asia Pacific is the second-largest regional market, with notable activity concentrated in China, Japan, South Korea and India. China anchors regional demand through its large base of contract research organizations and growing biotechnology sector, while Japan contributes through established life sciences tool makers with strong single-cell and genomics product portfolios. South Korea adds further activity through specialized gene-editing technology developers, and India is adding screening capacity as its biotechnology and pharmaceutical outsourcing sectors expand. Government-backed biotechnology investment programs across several regional markets are accelerating local screening capability that might otherwise lag behind demand.

Rising contract research activity across the region is letting pharmaceutical and biotechnology customers from Europe and North America access lower-cost CRISPR screening services without sacrificing technical capability. Growing local manufacturing of screening reagents and libraries is reducing regional customers' reliance on imported products. Inconsistent intellectual property protection for gene-editing methods across individual countries in the region can complicate how multinational suppliers license their technology locally. Even so, the region's expanding contract research base and biotechnology investment keep Asia Pacific as the fastest-growing region for CRISPR screening through 2035.

⮞MilliporeSigma, the U.S. and Canada life science business of Merck KGaA, opened its Asia-Pacific Bioprocessing Production Center in Daejeon, South Korea, in October 2026, an investment of more than EUR 300 million described as its largest Life Science investment in Asia-Pacific to date. Regional manufacturing capacity of this kind from a listed supplier supports the localization of life science supply described above.

Europe CRISPR Screening Market Insights

Europe is the third-largest regional market, with notable demand concentrated in the United Kingdom, Germany and France. The United Kingdom anchors regional demand through its concentration of academic genome centers and government-backed functional genomics screening laboratories, while Germany and France contribute through established pharmaceutical research hubs and academic genomics institutes. Coordinated funding from national research councils is supporting dedicated CRISPR screening infrastructure that individual academic laboratories could not establish on their own. Established European contract research organizations maintain close working relationships with regional pharmaceutical customers running target discovery programs.

Government and charitable research funding bodies across the region continue to back large functional genomics initiatives that pair CRISPR screening infrastructure with industry co-funding partners. Growing collaboration between academic genome centers and pharmaceutical companies is extending screening capacity beyond what either could support independently. Slower regional biotechnology funding growth compared with North America and Asia Pacific is moderating the pace of new screening infrastructure investment. Even so, sustained public research funding and established pharmaceutical research hubs support continued, steady growth for CRISPR screening across European markets through 2035.

MEA & Latin America CRISPR Screening Market Insights

The Middle East and Africa is a smaller but rapidly growing market for CRISPR screening, with Saudi Arabia and the United Arab Emirates leading regional activity as state-backed investment funds build out national genomics and precision medicine infrastructure, while South Africa contributes through academic research institutes with established genomics programs. International life sciences tool suppliers are expanding distribution partnerships across Gulf countries as government-backed biobanking and precision medicine programs grow. Limited local screening reagent manufacturing capacity keeps the region reliant on imported libraries and kits even as regional research investment accelerates from a comparatively small starting point.

Latin America adds demand through growing academic genomics research and a developing contract research sector, with Brazil leading regional activity followed by Mexico, Argentina and Colombia. Academic genome centers across Brazil and Mexico support steady demand for screening libraries and reagents, while growing pharmaceutical research investment across the region adds further demand for target discovery screening services. Local reagent manufacturing capacity remains limited across the region, and currency volatility complicates long-term component sourcing agreements for multinational suppliers. Even so, expanding academic genomics research and pharmaceutical investment support a steady increase in regional CRISPR screening demand through 2035.

Market Dynamics:

Growth Drivers: Reagent and instrument demand from life sciences tool suppliers is expanding

Demand for the reagents, instruments and consumables that underpin CRISPR screening continues to grow as more laboratories across academia and industry adopt genome-scale screening as a standard early step in target discovery. This steady expansion in laboratory-level demand supports continued investment by established tool suppliers in new reagent formulations, automated liquid handling compatibility and higher-throughput instrument platforms. Suppliers that can keep pace with this demand through expanded manufacturing capacity are well positioned to capture a growing share of recurring consumable purchases.

A second driver is the commercial validation provided by approved CRISPR-based therapies, which demonstrates to drug developers that the target discovery work screening supports can translate into regulatory approval and patient benefit. This validation is encouraging more biopharmaceutical companies to invest earlier in screening-based target identification rather than relying solely on existing published literature and prior clinical experience. As more CRISPR-based therapies advance through development and toward approval in additional disease areas, this validation effect is expected to reinforce broader screening demand across the wider drug discovery industry.

Restraints: Patent disputes and supplier concentration create operational uncertainty

CRISPR screening and the broader gene-editing field rely on a web of foundational patents held by a relatively small number of academic institutions and companies, and disputes over these patents can create uncertainty for commercial users about which licenses they need to run certain types of screens or commercialize downstream discoveries. Smaller screening service providers and biotechnology customers with limited legal resources are particularly exposed to this uncertainty compared with larger, better-resourced competitors. This patent complexity can slow adoption of certain screening methods until licensing terms are clarified.

Reliance on a concentrated group of specialized library, reagent and sequencing suppliers also exposes screening customers to order backlogs and cost increases during periods of unusually high demand, since few alternative suppliers can quickly absorb overflow orders for custom guide RNA libraries or high-throughput sequencing capacity. This supplier concentration can be particularly disruptive for time-sensitive drug discovery programs that cannot easily substitute a different library design mid-project. Smaller academic laboratories with limited purchasing leverage are more exposed to these disruptions than large, well-resourced pharmaceutical customers.

Opportunities: AI-enabled discovery workflows are widening the addressable market

Artificial intelligence tools that help researchers design guide RNA libraries, predict off-target effects and interpret complex screening datasets are creating an opportunity for screening providers to offer higher-value, software-enabled services rather than competing purely on reagent price. Providers that can pair their existing library and reagent catalogs with AI-assisted design and analysis tools are well positioned to capture additional revenue per screening project compared with a standalone reagent sale. As more drug discovery programs adopt AI-assisted target identification workflows, this opportunity is expected to grow alongside, rather than instead of, traditional screening reagent demand.

A second opportunity lies in extending CRISPR screening capability to contract research organizations and smaller biotechnology companies in emerging markets that are building drug discovery capability without the budget to establish large internal screening teams. Suppliers that can offer accessible training, technical support and smaller-scale library formats suited to these customers can establish early relationships ahead of broader market maturity in these regions. This growing base of resource-constrained but ambitious screening customers lowers the barrier for established suppliers to expand their addressable market beyond their traditional large-pharmaceutical customer base.

CRISPR Screening Market Key Players:

• Revvity, Inc.

• Thermo Fisher Scientific Inc.

• Merck KGaA

• Cellecta, Inc.

• GeneCopoeia, Inc.

• Integrated DNA Technologies, Inc.

• bit.bio

• Horizon Discovery Ltd.

• Applied Biological Materials Inc.

CRISPR Screening Market Report Scope: